SCHEMBL2177061

SCHEMBL2177061

N#Cc1nnc(C(=O)O)[nH]1

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.38
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11236100 0.81
SCHEMBL10752092 0.75 LMNA (0.44) PIN1LMNA
Water SCHEMBL15332100 0.68 LMNA (0.35) LMNA
SCHEMBL12050697 0.65 LMNA (0.37) LMNA
SCHEMBL20023168 0.65
SCHEMBL4858369 0.65
SCHEMBL2941533 0.65
SCHEMBL11588433 0.65
SCHEMBL14770091 0.65
SCHEMBL17185638 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200317691-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2020-10-08 US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 US disclosed
US-9296726-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-03-29 US disclosed
US-20150051196-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-02-19 US disclosed
US-8895584-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-11-25 US disclosed
US-20140243382-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-08-28 US disclosed
US-8759347-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-20130281475-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2013-10-24 US disclosed
US-8481564-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2013-07-09 US disclosed
US-20110195960-A1 INHIBITORS OF C-FMS KINASE ILLIG CARL R 2011-08-11 US disclosed
US-7973035-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2011-07-05 US disclosed
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent ILLIG CARL R 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317691-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB PIN1 2472/4885LMNA 1620/4885
US-20130281475-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES PIN1 1780/4885LMNA 3217/4885
US-20150051196-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES PIN1 1780/4885LMNA 3217/4885
US-20140243382-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES PIN1 1780/4885LMNA 3217/4885
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB PIN1 2472/4885LMNA 1620/4885
US-20110195960-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES PIN1 1780/4885LMNA 3217/4885
US-20080275031-A1 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent MUSK, CHUK, CAMK4 PIN1 1392/4885LMNA 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.